Prevalence of Hepatitis B Surface Antigen Among Refugees Entering the United States Between 2006 and 2008
Prevalence of Hepatitis B Surface Antigen Among Refugees Entering the United States Between 2006 and 2008
复制标题
DOI：
10.1002/hep.23353
复制
发表时间：
2010-02-01
期刊：
影响因子：
13.5
通讯作者：
Weinbaum, Cindy M.
中科院分区：
文献类型：
--
作者：
Rein, David B.;Lesesne, Sarah B.;Weinbaum, Cindy M.
美国疾病控制与预防中心建议，对于来自乙肝表面抗原（HBsAg）患病率为>= 2%的国家或地区的外国出生人员，通过检测乙肝表面抗原（HBsAg）来识别慢性乙型肝炎病毒感染。然而，现有的有限数据表明哪些国家符合这一定义。为了解决这一数据缺口，我们估计了2006年至2008年间进入美国的难民中HBsAg的患病率。我们联系了各州难民卫生协调员，请他们报告2008年8月之前最近12个月期间在其管辖范围内进行筛查的难民人数、原籍国和HBsAg流行率。我们汇集了各个司法管辖区的数据，并计算了任何有超过30名难民进入美国的国家的流行率，如果没有按国家提供这种水平的数据，则考虑了各大洲。在联系的47个司法管辖区中，我们从31个司法管辖区获得了基本信息，其中9个司法管辖区报告了适用于31,980名难民（约42%的难民在观察期间进入美国）的HBsAg按原籍国流行情况。我们估计难民总体HBsAg患病率为2.8%（95%置信区间为2.6%-3.0%）。在有30名或更多难民进入美国的37个国家中，有25个国家的难民率为2%。来自非洲和东南亚的难民患病率最高，来自中东和中南美洲的难民患病率最低。在我们有比较数据的8个国家中，6个国家的HBsAg患病率低于1991年。(肝脏病学51:431 2010;434)。
The Centers for Disease Control and Prevention recommends hepatitis B surface antigen (HBsAg) testing to identify chronic hepatitis B virus infection for foreign-born persons from countries or regions with HBsAg prevalence of >= 2%. However, limited data exist to indicate which countries meet this definition. To address this data gap, we estimated the HBsAg prevalence among refugees entering the United States between 2006 and 2008. We contacted state refugee health coordinators and asked them to report the number of refugees, country of origin, and HBsAg prevalence among refugees screened in their jurisdiction during the most recently available 12-month period prior to August 2008. We pooled data across jurisdictions and calculated the prevalence for any country with more than 30 refugees entering the United States, and where this level of data was not available by country, continents were considered. Of the 47 jurisdictions contacted, we received basic information from 3 1, with nine jurisdictions reporting HBsAg prevalence by country of origin applicable to 31,980 refugees (approximately 42% of refugees entering the United States during the observation period). We estimated an HBsAg prevalence of 2.8% (95% confidence interval 2.6%-3.0%) for refugees overall. Of the 37 countries with 30 or more refugees entering the United States, 25 had a prevalence of >= 2%. Prevalence was highest among refugees from Africa and Southeast Asia, and lowest among refugees from the Middle East and South/Central America. In the eight countries for which we had comparison data, six had lower HBsAg prevalence than in 1991. (HEPATOLOGY 2010;51:431-434.)